What is a stock summary page? Click here for an overview.
Business Description
Amoy Diagnostics Co Ltd
ISIN : CNE1000034D3
Share Class Description:
SZSE:300685: Class ACompare
Compare
Traded in other countries / regions
300685.China Index Membership
SZSE Component Index IPO Date
2017-08-02Description
Amoy Diagnostics Co Ltd is the pharmaceutical company based in China. The company primarily focuses on molecular diagnostics for oncology precision medicine. It provides diagnostic products and services for medicine development and clinical oncology practice. The company's products include gene mutation, nucleic acid extraction, and molecular diagnostic kits comprising EGFR, RAS, ALK, BRAF, PIK3CA, and ROS1 testing kits.
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 19.5 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | 0.16 | |||||
Interest Coverage | 292.07 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 27.72 | |||||
Beneish M-Score | -2.54 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.2 | |||||
3-Year EBITDA Growth Rate | 15.9 | |||||
3-Year EPS without NRI Growth Rate | 17.8 | |||||
3-Year FCF Growth Rate | 16.4 | |||||
3-Year Book Growth Rate | 14.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 25.36 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 20.38 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 33.38 | |||||
9-Day RSI | 38.4 | |||||
14-Day RSI | 42.91 | |||||
3-1 Month Momentum % | 3.39 | |||||
6-1 Month Momentum % | 26.58 | |||||
12-1 Month Momentum % | 11.07 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 8.06 | |||||
Quick Ratio | 7.89 | |||||
Cash Ratio | 5.02 | |||||
Days Inventory | 65.79 | |||||
Days Sales Outstanding | 162.87 | |||||
Days Payable | 38.73 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.66 | |||||
Dividend Payout Ratio | 0.18 | |||||
3-Year Dividend Growth Rate | 0.2 | |||||
Forward Dividend Yield % | 0.66 | |||||
5-Year Yield-on-Cost % | 2.3 | |||||
3-Year Average Share Buyback Ratio | 0.1 | |||||
Shareholder Yield % | 0.59 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 84.74 | |||||
Operating Margin % | 30.96 | |||||
Net Margin % | 26.61 | |||||
FCF Margin % | 24.38 | |||||
ROE % | 18.2 | |||||
ROA % | 16.24 | |||||
ROIC % | 42.29 | |||||
3-Year ROIIC % | 25.58 | |||||
ROC (Joel Greenblatt) % | 55.54 | |||||
ROCE % | 19.98 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 29.41 | |||||
Forward PE Ratio | 24.04 | |||||
PE Ratio without NRI | 27.89 | |||||
Shiller PE Ratio | 52.8 | |||||
Price-to-Owner-Earnings | 34.94 | |||||
PEG Ratio | 1.99 | |||||
PS Ratio | 7.81 | |||||
PB Ratio | 5.12 | |||||
Price-to-Tangible-Book | 5.26 | |||||
Price-to-Free-Cash-Flow | 32.06 | |||||
Price-to-Operating-Cash-Flow | 28.6 | |||||
EV-to-EBIT | 22.46 | |||||
EV-to-Forward-EBIT | 23.36 | |||||
EV-to-EBITDA | 22.46 | |||||
EV-to-Forward-EBITDA | 20.82 | |||||
EV-to-Revenue | 6.71 | |||||
EV-to-Forward-Revenue | 6.06 | |||||
EV-to-FCF | 29.04 | |||||
Price-to-GF-Value | 0.62 | |||||
Price-to-Projected-FCF | 2.51 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.67 | |||||
Price-to-Graham-Number | 2.55 | |||||
Price-to-Net-Current-Asset-Value | 6.11 | |||||
Price-to-Net-Cash | 10.8 | |||||
Earnings Yield (Greenblatt) % | 4.45 | |||||
FCF Yield % | 3.16 | |||||
Forward Rate of Return (Yacktman) % | 12.23 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Amoy Diagnostics Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ¥) | 1,183.883 | ||
EPS (TTM) (Â¥) | 0.79 | ||
Beta | 1.77 | ||
3-Year Sharpe Ratio | -0.18 | ||
3-Year Sortino Ratio | -0.28 | ||
Volatility % | 38.53 | ||
14-Day RSI | 42.91 | ||
14-Day ATR (Â¥) | 0.693722 | ||
20-Day SMA (Â¥) | 23.5555 | ||
12-1 Month Momentum % | 11.07 | ||
52-Week Range (Â¥) | 17.2 - 28.79 | ||
Shares Outstanding (Mil) | 393.06 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 7 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Amoy Diagnostics Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Amoy Diagnostics Co Ltd Stock Events
Event | Date | Price (Â¥) | ||
---|---|---|---|---|
No Event Data |
Amoy Diagnostics Co Ltd Frequently Asked Questions
What is Amoy Diagnostics Co Ltd(SZSE:300685)'s stock price today?
The current price of SZSE:300685 is ¥23.23. The 52 week high of SZSE:300685 is ¥28.79 and 52 week low is ¥17.20.
When is next earnings date of Amoy Diagnostics Co Ltd(SZSE:300685)?
The next earnings date of Amoy Diagnostics Co Ltd(SZSE:300685) is .
Does Amoy Diagnostics Co Ltd(SZSE:300685) pay dividends? If so, how much?
The Dividend Yield %  of Amoy Diagnostics Co Ltd(SZSE:300685) is 0.66% (As of Today), Highest Dividend Payout Ratio of Amoy Diagnostics Co Ltd(SZSE:300685) was 0.58. The lowest was 0.18. And the median was 0.24. The  Forward Dividend Yield % of Amoy Diagnostics Co Ltd(SZSE:300685) is 0.66%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |